Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
Sponsor: Takeda
Terminated
Business Decision; No Safety Or Efficacy Concerns
Other terminated trials from Takeda
Other Diabetes Mellitus, Type 2 trials with similar outcome
Listed as NCT02989649, this observational or N/A phase trial focuses on Diabetes Mellitus, Type 2 and remains terminated or withdrawn. Sponsored by Takeda, it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
May 2019 — Jan 2021 [monthly]
Terminated
▶ Show 5 earlier versions
-
Jun 2018 — May 2019 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Feb 2017 — Mar 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting · Phase: PHASE4 → NA
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Dalian, China , Jinan, China , Qingdao, China , Sai Ying Pun, Hong Kong , Shatin, Hong Kong , Shenyang, China , Taian, China , Tai’an, China , Tianjin, China and 1 more location